Pimavanserin · Nuplazid
Small molecule
Also known as ACP-103
Evidence outlook
Approved: Parkinson's Disease Psychosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00477672 NCT00477672 · Parkinson's Disease Psychosis This was a randomized, quadruple-blind, placebo-controlled trial with 298 participants and a clinical symptom-scale primary endpoint. The primary comparison was not statistically significant: the confidence intervals for both pimavanserin doses versus placebo included no difference, so the trial provides well-controlled but negative or inconclusive evidence of benefit. Registry: NCT00477672 | 3 | Antipsychotic Efficacy (Each study visit (i.e. Days 1, 8, 15, 29 and 42)) 2009-06 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 4 more trials
NCT01174004 NCT01174004 · Parkinson's Disease Psychosis Registry: NCT01174004 | 3 | Antipsychotic Efficacy (Each study visit (i.e. Days 1, 15, 29 and 43)) 2012-11 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
NCT06068465 NCT06068465 · Parkinson's Disease Psychosis The trial randomized 248 participants to pimavanserin or placebo and used quadruple masking. Its primary clinical endpoint was the change in SAPS-PD score at day 43, but results have not been posted, so it is not yet possible to determine whether the primary endpoint was met. Registry: NCT06068465 | 3 | The primary outcome is change in total SAPS-PD score from baseline to day 43. (Assessments are done at baseline and days 15,29 and 43.) 2026-02-01 | Results not posted; external-source review pending | Partial signal | link ↗ |
NCT00550238 NCT00550238 · Parkinson's Disease Psychosis Registry: NCT00550238 | 3 | Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) (From first to last study drug dose plus 30 days) 2018-05-30 | Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs) (From first to last study drug dose plus 30 days): Pimavanserin 180 Participants | not yet graded | link ↗ |
NCT00658567 NCT00658567 · Parkinson's Disease Psychosis Registry: NCT00658567 | 3 | Antipsychotic Efficacy (Each study visit (i.e. Days 1, 8, 15, 29 and 42)) 2009-12 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
Other Serotonin 5-HT2A receptor (antagonist / inverse agonist) drugs
Remlifanserin, Roluperidone, Sarpogrelate, Deramciclane, LY03017. Compare all 6 Serotonin 5-HT2A receptor (antagonist / inverse agonist) drugs
Other 5-HT2A/2C receptor drugs
5 other tracked programmes target this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pimavanserin (Nuplazid): this drug | Approved | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/2C receptor | Partial signal | NCT04531982: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 (26 Weeks Treatment Duration): Drug - Pimavanserin -12.14 score on a scale (Standard Deviation 10.29) vs Placebo -11.09 score on a scale (Standard Deviation 9.18) missed | |
| Remlifanserin | Phase 3(overall) | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary | |
| Roluperidone | Phase 3(overall) | Small molecule | Sigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist) | Partial signal | NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed | |
| Sarpogrelate (Anplag) | Phase 3(overall) | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary | |
| Deramciclane | Phase 2/3(overall) | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary | |
| LY03017 | Phase 2(overall) | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptor | Weak signal | No reviewed efficacy summary |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nuplazid (Pimavanserin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
2028 (1)
June 2028 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
2031 (1)
December 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent